ALG-1007 is under clinical development by Allegro Ophthalmics and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ALG-1007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALG-1007 is under development for the treatment of dry eye disease. The therapeutic candidate is formulated as drops-solution and is administered through ophthalmic route. It acts by targeting integrin alpha V and Beta 1,2 and 3.
Allegro Ophthalmics overview
Allegro Ophthalmics is an ophthalmic pharmaceutical company. The company uses integrin-regulating therapy for the treatment of vascular eye diseases. Allegro Ophthalmics is headquartered in San Juan Capistrano, California, the US.
For a complete picture of ALG-1007’s drug-specific PTSR and LoA scores, buy the report here.